| Product Code: ETC6653085 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Canada Circulating Tumor DNA (ctDNA) Market Overview |
3.1 Canada Country Macro Economic Indicators |
3.2 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, 2021 & 2031F |
3.3 Canada Circulating Tumor DNA (ctDNA) Market - Industry Life Cycle |
3.4 Canada Circulating Tumor DNA (ctDNA) Market - Porter's Five Forces |
3.5 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.6 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume Share, By Sample, 2021 & 2031F |
3.7 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume Share, By Method, 2021 & 2031F |
3.8 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 Canada Circulating Tumor DNA (ctDNA) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Canada |
4.2.2 Advancements in liquid biopsy technologies |
4.2.3 Growing adoption of personalized medicine in oncology |
4.3 Market Restraints |
4.3.1 High costs associated with ctdna testing |
4.3.2 Lack of reimbursement policies for ctdna testing |
4.3.3 Limited awareness among healthcare professionals and patients about ctdna testing |
5 Canada Circulating Tumor DNA (ctDNA) Market Trends |
6 Canada Circulating Tumor DNA (ctDNA) Market, By Types |
6.1 Canada Circulating Tumor DNA (ctDNA) Market, By Application |
6.1.1 Overview and Analysis |
6.1.2 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Application, 2021- 2031F |
6.1.3 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Routine Screening, 2021- 2031F |
6.1.4 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Patient Work Up, 2021- 2031F |
6.1.5 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Early-Stage Disease, 2021- 2031F |
6.1.6 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Late Stage/Metastatic Disease, 2021- 2031F |
6.2 Canada Circulating Tumor DNA (ctDNA) Market, By Sample |
6.2.1 Overview and Analysis |
6.2.2 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Blood, 2021- 2031F |
6.2.3 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Urine, 2021- 2031F |
6.2.4 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Canada Circulating Tumor DNA (ctDNA) Market, By Method |
6.3.1 Overview and Analysis |
6.3.2 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Sample Preparation, 2021- 2031F |
6.3.3 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Ultra-Low Passage Whole Genome Sequencing,, 2021- 2031F |
6.3.4 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By ctDNA Quantification, 2021- 2031F |
6.3.5 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Copy Number Analysis, 2021- 2031F |
6.3.6 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Statistical Analysis, 2021- 2031F |
6.4 Canada Circulating Tumor DNA (ctDNA) Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Research Laboratories, 2021- 2031F |
6.4.4 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Academia, 2021- 2031F |
6.4.5 Canada Circulating Tumor DNA (ctDNA) Market Revenues & Volume, By Research Centers, 2021- 2031F |
7 Canada Circulating Tumor DNA (ctDNA) Market Import-Export Trade Statistics |
7.1 Canada Circulating Tumor DNA (ctDNA) Market Export to Major Countries |
7.2 Canada Circulating Tumor DNA (ctDNA) Market Imports from Major Countries |
8 Canada Circulating Tumor DNA (ctDNA) Market Key Performance Indicators |
8.1 Adoption rate of liquid biopsy technologies in Canada |
8.2 Number of clinical trials incorporating ctdna testing |
8.3 Percentage of oncologists recommending ctdna testing for cancer patients |
9 Canada Circulating Tumor DNA (ctDNA) Market - Opportunity Assessment |
9.1 Canada Circulating Tumor DNA (ctDNA) Market Opportunity Assessment, By Application, 2021 & 2031F |
9.2 Canada Circulating Tumor DNA (ctDNA) Market Opportunity Assessment, By Sample, 2021 & 2031F |
9.3 Canada Circulating Tumor DNA (ctDNA) Market Opportunity Assessment, By Method, 2021 & 2031F |
9.4 Canada Circulating Tumor DNA (ctDNA) Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 Canada Circulating Tumor DNA (ctDNA) Market - Competitive Landscape |
10.1 Canada Circulating Tumor DNA (ctDNA) Market Revenue Share, By Companies, 2024 |
10.2 Canada Circulating Tumor DNA (ctDNA) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |